MYO — Myomo Inc.
Is MYO overbought or oversold? Here is the current MarketMoodz read.
Myomo Inc. (MYO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.02. The rating moved from Overbought to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$1.02
- Last changeMoved from Overbought to Oversold on November 13, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Myomo Inc. operates in a defensible clinical niche with product-market fit for upper-limb assistance and benefits from secular tailwinds toward at‑home and outpatient care. Financially the company shows constrained liquidity and small-scale commercialization, making near-term growth and profitability dependent on tight execution, reimbursement wins, and likely capital raises. Commercial traction, distribution expansion (including VA/DME channels) and clearer payer coverage would drive upside, while dilution risk, slow adoption and competition present meaningful downside. Given the mix of clear use-case potential but material execution and financing risk, near-term price movement is likely to remain choppy until outcomes on reimbursement and funding become clearer.
Key factors
- Niche market position in wearable myoelectric orthoses with clear clinical use cases (upper-limb neuromuscular impairment)
- Exposure to growing at‑home and outpatient care trends that favor home-use rehabilitation devices
- Modest but recurring revenue streams from device sales, service contracts, and possible VA/DME channels
- Limited scale and liquidity: small market cap, low daily volume and constrained balance sheet
- Reimbursement and payer coverage dynamics remain central to commercial adoption and revenue growth
- Potential near-term commercial catalysts from expanded distribution or targeting Medicare Advantage/home-care channels
Risks
- High cash burn and likelihood of additional equity or convertible financing that could dilute shareholders
- Uncertain or limited payer reimbursement and slow adoption by clinicians and patients
- Competition and innovation risk from larger device makers and emerging diabetes/remote-care device players
- Operational execution risk given small commercial team and constrained resources
- Regulatory and product liability risks inherent to medical devices
- Low social/research visibility and limited institutional coverage, increasing volatility and information asymmetry
See today's live rating, score and targets
Members see the live hourly rating for MYO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.